NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−1.02%Oct 30, 2026, 13:14 UTC
NextCure said Chief Medical Officer Dr. Udayan Guha will depart effective October 31, 2026, and will receive severance benefits under his employment agreement, with additional change-in-control severance conditional on the merger closing.
Sep 3, 2026, 20:20 UTC
NextCure, Inc. amended its lease agreement, accelerating the lease expiration to December 31, 2027, terminating rent obligations as of September 1, 2026, and paying a lump sum of $758,648 while forfeiting a $39,292.70 security deposit.
Aug 10, 2026, 13:00 UTC
Xcellon Biologics acquires a GMP manufacturing facility from NextCure, becoming an end-to-end CRDMO for next-generation bioconjugates and complex biologics.
Jul 14, 2026, 10:24 UTC
Avere, an investee of Hansoh Pharmaceutical, merges into NextCure via a merger agreement, with Hansoh expected to hold more than 30% of the combined entity's equity.
Jun 25, 2026, 00:00 UTC
NextCure, Inc. elected Anne Borgman, M.D. and John G. Houston, Ph.D. as Class I members of its Board of Directors, effective June 18, 2026.